Back to search results

Consolidative Therapy for Metastatic Kidney Cancer

This study is looking at a treatment approach called consolidative Metastasis and Primary Directed Therapy (MPDT) for people with metastatic clear cell renal cell carcinoma (a type of kidney cancer). MPDT involves procedures like surgery, cryoablation (freezing cancer cells), or radiation therapy after you've already received at least six months of immune checkpoint blockade-based therapy. You might be able to join if you have clear cell kidney cancer that has spread, with five or fewer metastases (new cancer growths) and your cancer is stable or has partially responded to your current treatment. The study wants to see how many people can stop systemic anti-cancer therapy after MPDT and remain treatment-free for 12 months. This is a Phase II study and plans to enroll 23 participants.

Study design
This is a Phase II study that is not randomized and is open-label, meaning everyone knows what treatment is being given. It plans to enroll 23 participants.
What's involved
After stopping your current systemic anti-cancer therapy, you would receive one or more procedures such as surgery, cryoablation, or radiation therapy.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed to see how long they remain treatment-free, up to 60 months (5 years).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06770855

Consolidative Metastasis and Primary Directed Therapy (MPDT) for Renal Cell Carcinoma (RCC)

Not Yet Recruiting
NAAges 18+InterventionalTreatment
Abramson Cancer Center at Penn Medicine
~23 participants
Updated 2026-06-23 on ClinicalTrials.gov
What's tested:Total consolidative MPDT

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Treatment-free survival
Measured over From discontinuation of anti-cancer therapy until resumption of systemic therapy, first date of additional focally-directed therapy or death, whichever comes first, assessed up to 60 months.

Conditions

Renal Cell Carcinoma

Explore related trials

Renal Cell Carcinoma

Where it's being run

1 sites across 1 states
Pennsylvania1

Study leadership

  • Naomi Haas, MD · PRINCIPAL_INVESTIGATOR · Penn Medicine

Who to contact

Matthew Doyle
[email protected]
610-357-6354
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Histologically or cytologically confirmed diagnosis of clear cell renal cell carcinoma (mixed histology acceptable but must have clear cell component)
Metastatic clear cell RCC with 5 or fewer metastases at enrollment (excluding pulmonary nodules \<1.0cm)
Stable disease or partial response as assessed by investigators following at least 6 months of immune checkpoint blockade-based therapy.
Has disease amenable for total consolidative focal therapy (this will be determined by a multidisciplinary team which may include a combination of medical oncologists, urologists, interventional radiologists, and radiation oncologists).
ECOG performance status \< 2
Must have archival tissue (slide or Formalin-Fixed Paraffin-Embedded tissue) preceding prior systemic treatment for comparison to tissue from consolidation
Consolidation surgery and biopsies are strongly encouraged to be within 42 days +/- 7 days of holding systemic therapy.

Exclusion

Subjects who have progressed during the first 6 months of immune checkpoint-blockade based therapy as determined by study investigator.
Subjects who have a need for urgent focally directed therapy (i.e. symptomatic brain or spinal metastases). Stable spinal metastases resected and/or treated with SBRT in advance of or concurrently with immune checkpoint-blockade based therapy are allowed to participate.
Any female of child-bearing potential who has a positive urine pregnancy test within 72 hours before screening. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. Participants must be excluded/discontinued from the trial in the event of a positive or borderline positive serum pregnancy test result.

What this trial measures

  • Treatment-free survivalFrom discontinuation of anti-cancer therapy until resumption of systemic therapy, first date of additional focally-directed therapy or death, whichever comes first, assessed up to 60 months.

    Treatment-free survival, defined as the time from discontinuation of anti-cancer therapy until either: 1) the resumption of systemic therapy; 2) the first date of additional focally-directed therapy; or 3) death.